Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 15,142 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

NCT05161208
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

NCT04163991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
VIB4920, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Anniston, Alabama • Sun City, Arizona • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 1 Interventional

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

NCT04418297
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
CT-G20, Placebo
Drug
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Not listed Phase 4 Interventional

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

A Study Of TL-925 For The Treatment of AC

NCT06293820
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

NCT04043923
View directory record Official record
Conditions
Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Potassium Intake in Patients With Chronic Kidney Disease

NCT00949585
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Dietary intake of potassium
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation

NCT01066585
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin Cream, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Yuma, Arizona • Dinuba, California • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
111
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 31, 2026, 2:11 PM EDT
Not listed Phase 2 Interventional

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

NCT05311215
View directory record Official record
Conditions
Spasticity
Interventions
SL-1002, Placebo
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

NCT01367535
View directory record Official record
Conditions
Healthy Adults
Interventions
SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 31, 2026, 2:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • La Jolla, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

NCT00967382
View directory record Official record
Conditions
Pregnancy, Thrombophilia, Pregnancy Complications
Interventions
dalteparin sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 3 Interventional

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT01208168
View directory record Official record
Conditions
Onychomycosis
Interventions
NAB001, Vehicle alone
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Phoenix, Arkansas • Encino, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 31, 2026, 2:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

PRESERVE & CONNECT: Impact Study of the BPC

NCT06160050
View directory record Official record
Conditions
Child Maltreatment, Trauma
Interventions
Breakthrough Parenting Curriculum: Transforming trauma across generations
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Hartford, Connecticut • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

NCT07724340
View directory record Official record
Conditions
Adults With Overweight/Obesity and Type 2 Diabetes
Interventions
AT673 low dose, AT673 high dose, Placebo
Drug
Lead sponsor
Antag Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Chandler, Arizona • Anaheim, California • Hollywood, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

VEC-162 Study in Adult Patients With Primary Insomnia

NCT00548340
View directory record Official record
Conditions
Primary Insomnia
Interventions
VEC-162 20 mg, Placebo, VEC-162 50 mg
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 31, 2026, 2:11 PM EDT